Summary
Eli Lilly and Company (LLY) announced on February 20, 2019, its entry into an Underwriting Agreement to issue and sell a substantial amount of senior notes. This offering includes four tranches of notes with varying maturity dates and interest rates: $1.15 billion in 3.375% Notes due 2029, $850 million in 3.875% Notes due 2039, $1.5 billion in 3.950% Notes due 2049, and $1 billion in 4.150% Notes due 2059. The total aggregate principal amount of the offering is $4.5 billion. The company expects to receive net proceeds of approximately $4.45 billion after deducting the underwriter's discount, which are anticipated to be available by February 22, 2019. This significant debt issuance suggests that Lilly is securing long-term financing, potentially to fund ongoing research and development, capital expenditures, or other strategic initiatives. Investors should consider the implications of this increased debt load on the company's financial leverage and future interest expenses.
Key Highlights
- 1Eli Lilly entered into an Underwriting Agreement on February 20, 2019, to issue new senior notes.
- 2The total aggregate principal amount of the notes offered is $4.5 billion.
- 3The offering comprises four tranches: $1.15B (3.375% due 2029), $850M (3.875% due 2039), $1.5B (3.950% due 2049), and $1B (4.150% due 2059).
- 4The closing of the offering is expected on February 22, 2019.
- 5Net proceeds are estimated to be approximately $4.45 billion after underwriter discounts.
- 6The notes are issued under an Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as trustee.
- 7The filing details the terms and conditions for potential default, acceleration, and redemption of the notes.